Back to top
more

Luminex Corporation (LMNX)

(Delayed Data from NSDQ)

$23.70 USD

23.70
234,048

+0.60 (2.60%)

Updated May 3, 2019 04:00 PM ET

After-Market: $23.71 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

LHC Group (LHCG) Forays Into Oregon With New Acquisition

by Zacks Equity Research

LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.

PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout

by Zacks Equity Research

PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.

Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B

by Zacks Equity Research

Luminex (LMNX) to be acquired by DiaSorin for around $1.8 billion. This is likely to advance its technology and solutions' foothold outside the United States.

Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?

by Zacks Equity Research

Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

Luminex (LMNX) Files EUA Application for New Respiratory Assay

by Zacks Equity Research

Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.

Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Luminex (LMNX) Q4 Earnings Miss Estimates

by Zacks Equity Research

Luminex (LMNX) delivered earnings and revenue surprises of -92.86% and 0.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Why Is Luminex (LMNX) Down 0.8% Since Last Earnings Report?

by Zacks Equity Research

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Luminex (LMNX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Luminex (LMNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Luminex (LMNX) Down 34.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

by Zacks Equity Research

Investor confidence is high on Luminex (LMNX) stock, thanks to solid prospects.

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Luminex (LMNX) Q2 Earnings Surpass Estimates

by Zacks Equity Research

Luminex (LMNX) delivered earnings and revenue surprises of 237.50% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth (CGC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued momentum from robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.

Illumina (ILMN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its second-quarter sequencing consumable revenue growth.

Luminex (LMNX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Luminex (LMNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test

by Zacks Equity Research

Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.

    Luminex (LMNX) Catches Eye: Stock Jumps 7.1%

    by Zacks Equity Research

    Luminex (LMNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    Here's Why You Should Retain Luminex (LMNX) Stock for Now

    by Zacks Equity Research

    Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.